Journal
FRONTIERS IN IMMUNOLOGY
Volume 13, Issue -, Pages -Publisher
FRONTIERS MEDIA SA
DOI: 10.3389/fimmu.2022.943916
Keywords
radioactive iodine refractory; differentiated thyroid cancer; combination immunotherapy; multitargeted kinase inhibitors plus PD-1; PD-L1 inhibitors therapy; apatinib plus camrelizumab treatment
Categories
Funding
- CAMS Innovation Fund for Medical Sciences (CIFMS) [2020-I2M-2-003]
- CSCO-Hengrui Research Foundation [Y-HR2018-143, Y-HR2018-144]
- National Natural Science Foundation of China [81771875]
- Project on Inter-Governmental International Scientific and Technological Innovation Cooperation in the National Key Projects of Research and Development Plan [2019YFE0106400]
Ask authors/readers for more resources
This case report presented a 43-year-old male patient with RAIR DTC who showed disease control and partial response to combination immunotherapy of apatinib plus camrelizumab after resistance to first-line therapy. Long-term mild efficacy was observed with occasional diarrhea as the main adverse event.
BackgroundPatients with radioactive iodine refractory progressive (RAIR) differentiated thyroid cancer (DTC) often developed resistance after first-line therapy. Apatinib plus camrelizumab is a therapy with promising efficacy in patients with other malignant cancers. Herein, we presented a case of progressive RAIR DTC treated with apatinib plus camrelizumab. Case presentationWe reported a 43-year-old man diagnosed as DTC with metastases in the lungs, the 7th cervical vertebra, and malignant lymph nodes mainly in the mediastinum. While initially showing disease stabilization after giving the first-line multitargeted kinase inhibitor (MKI) therapy, the patient developed progressive disease and was enrolled into a combined therapy with both apatinib and camrelizumab on November 10, 2020. Upon the first 6 months, the combination therapy showed disease control in terms of both stable structural lesions and biochemical thyroglobulin (Tg) level. Six months later, a decrease over the targeted lesions was observed and a partial response (PR) according to RECIST 1.1 criteria was finally achieved upon 12 months' assessment, followed by the decline in serum Tg level. The main adverse event was occasional diarrhea without treatment interruption. ConclusionWe reported a case with RAIR DTC that benefited from combination immunotherapy, apatinib plus camrelizumab, after resistance from donafenib. We observed a gradually getting better efficacy and a mild and long duration of this combination therapy and hoped to provide a therapeutic choice for these patients.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available